Danone is strengthening its Specialised Nutrition business in China with a series of investments totalling €100 million.
This will enable uniquely the company to broaden and deepen its range of nutritional products and services that are tailored to Chinese health needs, traditions and tastes.
The investments include the opening of an open-science research centre based in Shanghai, the acquisition of local infant milk formula capabilities, and the expansion of capacity to further develop offerings in FSMP (Food for Special Medical Purposes).
Danone’s Early Life Nutrition business unit in the country has achieved B Corp certification, making the company the biggest B Corp in Asia.
It is the latest step towards the company’s accelerated ambition to become B Corp™ certified by 2025.
“The opening of the Open Science Research Centre, the acquisition of local manufacturing capabilities and the B Corp certification are key milestones for Danone’s presence in China as they will allow us to further invest responsibly in the promotion of healthy and balanced diets, grounded in scientific research and tailored to Chinese nutritional and health needs, habits, and traditions,” said Véronique Penchienati-Bosetta, Executive Vice President of Specialised Nutrition.
“This investment further demonstrates Danone’s belief in the long-term growth potential of the Infant Milk Formula and medical nutrition market in China and in the power of nutrition to positively impact health trajectories.”